



Case Report

All-*trans* retinoic acid-induced, life-threatening complete atrioventricular block

Chen-Hsiang Shih^a, Hung-Bo Wu^{b,*}

^a Division of Cardiology, Department of Medicine, Edah Hospital, Kaohsiung, Taiwan, ROC

^b Division of Hematology Oncology, Department of Medicine, Taipei City Hospital, Renai Branch, Taipei, Taiwan, ROC

Received March 3, 2014; accepted May 21, 2014

Abstract

We report a case of complete atrioventricular block (CAVB) with ventricular asystole and recurrent AVBs due to all-*trans* retinoic acid (ATRA). A 57-year-old man with acute promyelocytic leukemia was undergoing induction therapy with ATRA and developed episodic seizures with altered consciousness on the 14th day and then CAVB followed by cardiac arrest on the 15th day. Although he initially recovered after resuscitation, he suffered from recurrent CAVB, which persisted for 3 days despite immediate ATRA discontinuation. He then received ATRA retreatment with reduction of dosage, but a high-degree AVB recurred on the 5th day. After discontinuation of ATRA therapy, the patient recovered 3 days later without any cardiovascular event during follow-up. The serial electrocardiogram changes suggested an infra-Hisian block with possible ATRA dose-response relationship. To our knowledge, this is the first established case of ATRA-induced CAVB in the literature. We suggest clinical alertness for this life-threatening complication.

Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

Keywords: acute promyelocytic leukemia; all-*trans* retinoic acid; arrhythmia; complete atrioventricular block

1. Introduction

Acute promyelocytic leukemia (APL) comprises 10–15% of acute myelocytic leukemia and is characterized by marked proliferation of leukemic promyelocytes in the bone marrow, life-threatening coagulopathy, and a specific reciprocal translocation of t(15;17). APL used to be a highly lethal subtype of acute leukemia, with up to a 47% early hemorrhagic death rate before or during induction chemotherapy and a 2-year survival of 30–50%.¹ However, the advent of all-*trans* retinoic acid (ATRA) in the 1980s revolutionized the therapy of APL,

leading to dramatic decreases in early hemorrhagic death, to 5–10%, and overall survival, to 85–90%.²

Herein, we report a case of APL developing a very rare but life-threatening CAVB during ATRA therapy. The causal role of ATRA was established by rechallenge, and the serial electrocardiogram (EKG) changes suggested a possible dose-response relationship.

2. Case report

A 57-year-old man with type II diabetes mellitus was admitted due to fever and leukopenia. The blood routine revealed leukopenia ($1.6 \times 10^9/L$), anemia (10 g/dL), and thrombocytopenia ($24 \times 10^9/L$) with immature white cells. The bone marrow study suspected APL, but septicemia due to *Acinetobacter baumannii* had to be treated during the initial course with intravenous ciprofloxacin that was later changed to cefepime due to persistent fever.

Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.

* Corresponding author. Dr. Hung-Bo Wu, Division of Hematology Oncology, Department of Medicine, Taipei City Hospital, Renai Branch, 10, Section 4, Renai Road, Taipei 106, Taiwan, ROC.

E-mail address: hbwuusa@yahoo.com (H.-B. Wu).

After bone marrow cytogenetics confirmed a three-loci translocation of APL [46, XY, t(15;22;17)(q24;q13;q21)], ATRA (45 mg/m²/d) was given orally. The patient experienced an ATRA-related mild headache and bone pain, but mucositis became aggravated later and the dosage was reduced to 75% from the 5th day of therapy. Molecular study reported a long-type PML/RAR α fusion mRNA 2 weeks later.

On the 13th day of ATRA therapy, an episode of transient aphasia and general paresis occurred, but urgent computed tomography of the brain showed negative results. On the following day, the patient then developed episodic generalized convulsions with delirium. Laboratory surveys revealed no significant abnormalities. Valproic acid was given under suspicion of myoclonic seizure to relieve the symptoms.

On the 15th day of ATRA therapy, the patient experienced another episode of fluctuating consciousness disturbance in the morning. Bedside EKG monitoring showed a first-degree AVB with a regular heartbeat of 94 beats/min (Fig. 1A), and later, the EKG showed CAVB with ventricular escape (Fig. 1B). In the afternoon, a complete loss of consciousness suddenly occurred after yawning. The patient was found unresponsive and without spontaneous breathing or heartbeat. A shot of epinephrine was given immediately followed by cardiopulmonary resuscitation. The ventricular rate resumed after treatment, but severe bradycardia recurred due to CAVB 2 hours later, necessitating a second resuscitation.

We stopped the ATRA therapy and administered temporary cardiac pacing for the patient; an echocardiogram did not demonstrate any structural defect of the heart, but varying degrees of heart blocks persisted for 3 days (Fig. 2A–C)

before conversion to sinus rhythm on the 20th day. Due to suspicion of ATRA as the inciting agent, we reduced its dose during retreatment and placed the patient under close EKG telemetric monitoring. However, on the 5th day of treatment, high-degree AVB with 2:1 AV conduction (Fig. 2D) recurred without significant clinical symptoms. The drug was discontinued immediately, and the AVB disappeared gradually over 3 days without further recurrence. Throughout the episodes, there was no evidence of retinoic acid syndrome (RAS), such as the characteristic features of fever, respiratory distress, pulmonary infiltration, pleural or pericardial effusion, or weight gain, nor did the patient receive any arrhythmogenic or node-blocking medication.

3. Discussion

The retinoid acids are derived from vitamin A, and bind to the nuclear retinoic acid receptors (RARs). The RARs then undergo heterodimerization and bind to DNA to facilitate gene transcription and control post-transcriptional expression. The t(15;17) translocation of APL fuses the *PML* (promyelocytic leukemia) gene to the gene *RAR α* , and the resultant fusion gene *PML-RAR α* produces the PML/RAR α oncoprotein, which forms homodimer and competitively blocks granulocytic differentiation.² The pharmacological dose of ATRA leads to dissociation of the nuclear corepressor, which presumably facilitates APL maturation.³

ATRA has been a relatively safe drug, with few serious adverse effects as compared to conventional chemotherapy. The more common side effects, including headache, dry




Fig. 1. Serial electrocardiogram changes before and after the life-threatening complete atrioventricular block (AVB): (A) 7 hours before cardiac arrest: first-degree AVB (P-R interval = 360 ms); (B) 2 hours before cardiac arrest: complete AVB with ventricular escape (15th day of all-*trans* retinoic acid).



Fig. 2. Delayed recovery of heart blocks with recurrence after rechallenge: (A) 38 hours after resuscitation: second-degree atrioventricular block (AVB; Mobitz type I); (B) 63 hours after resuscitation: complete AVB with pacing-dependence and intermittent ventricular asystole; (C) 91 hours after resuscitation: first-degree AVB; and (D) recurrence of high-degree AVB on Day 5 of all-*trans* retinoic acid rechallenge.

skin, xerostomia, cheilitis, bone pain, and arthralgia, are usually mild. RAS is a special side effect of ATRA, and occurs in 15% of APL patients during the 2nd day to the 3rd week of ATRA therapy, with a mortality rate of 2%. The proposed mechanisms of RAS include release of vasoactive cytokines from cytoplasmic granules, expression of surface adhesion molecules, and chemotaxis of differentiating myeloid cells. Prompt administration of high-dose dexamethasone at the first signs of unexplained dyspnea, weight gain, fever, and pulmonary infiltrate is critical for an optimal outcome.⁴

ATRA-related arrhythmias are rarely reported in the literature. A case of Wenckebach phenomenon was reported with RAS-related pericardial effusion on the 9th day of ATRA therapy but recovered after steroid treatment.⁵ Recurrent sinus bradycardias due to ATRA during APL treatment was reported in a 3-year-old boy.⁶ Sinus node dysfunction with

asymptomatic junctional bradycardia was also reported in a 28-year-old woman after sepsis and RAS related to ATRA and anthracycline-based chemotherapy.⁷

There was only one previous case report of suspected ATRA-related CAVB, which was reported in the Japanese literature.⁸ The CAVB presented as an unexplained sudden Adams–Stokes syncope on the 25th day of induction therapy after enocitabine, mitoxantrone, and ATRA therapy. The cause of CAVB was uncertain, hence ATRA was given for 4 more days before discontinuation; the arrhythmia persisted for 15 days before recovery.⁸

The mechanism underlying ATRA-related heart blocks is unknown. A previous study of an ischemia–reperfusion model in rats reported that a perfusion of ATRA (15–20 μM) could significantly reduce the incidence and severity of ventricular arrhythmias. The authors speculated that inhibition of automaticity/excitability may result from effects of ATRA on

membrane ion channels which make the cardiac cells less responsive to stimuli.⁹ In our case, the first attack of CAVB occurred on the 15th day of ATRA therapy and then persisted for 3 days. Under low-dose rechallenge, the second attack was milder and shorter, occurred as asymptomatic high-grade AVB on the 5th day, and persisted for 3 days. The onset and severity of the heart blocks in our case may suggest a possible relationship between the drug level and the AV blocks. According to the devastating clinical course and wide QRS complex of the escape rhythm, the level of conduction block may have been due to an infra-Hisian block. Considering the very rare occurrence and the dosage-temporal pattern with ATRA usage in this case, we suspect that idiosyncratic myocardial sensitivity or heterogeneity in drug metabolism may have played a part in its pathogenesis.

A recent population-based survey in the USA revealed a much higher early death rate, of 17.3%, than those reported in modern trials, due to therapy delays during diagnostic workups. Since current guidelines advocate regarding suspicion of APL as a medical emergency necessitating prompt commencement of ATRA therapy prior to genetic confirmation, awareness of this life-threatening complication is important for clinicians.¹⁰

In this case report, we have established the causal relationship of ATRA and CAVB by rechallenge. Although the pathophysiology was obscured, the serial EKG changes of this case suggest a possible dose–response effect. Further exploration into the myocardial electrophysiology of ATRA is necessary to disclose the underlying mechanisms and the drug's potential role in the management of cardiac arrhythmia.

References

1. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. *Blood* 1992;**79**:543–53.
2. Warrell Jr RP, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. *N Engl J Med* 1993;**329**:177–89.
3. Guidez F, Ivins S, Zhu J, Söderström M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. *Blood* 1998;**91**:2634–42.
4. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. *J Clin Pharm Ther* 2008;**33**:331–8.
5. Dhar AK, Barman PK. Retinoic acid syndrome: cardiac complication. *J Assoc Physicians India* 2012;**60**:63–5.
6. Maruhashi K, Wada H, Taniguchi M, Koizumi S. Sinus bradyarrhythmia during administration of all-trans retinoic acid in a patient with acute promyelocytic leukemia. *Rinsho Ketsueki* 1996;**37**:443–7 [in Japanese].
7. McGregor A, Hurst E, Lord S, Jones G. Bradycardia following retinoic acid differentiation syndrome in a patient with acute promyelocytic leukaemia. *BMJ Case Rep* 2012. <http://dx.doi.org/10.1136/bcr.02.2012.5848>.
8. Yamauchi T, Arai H, Taga M, Amaya N, Lee JD, Ueda T. Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid. *Rinsho Ketsueki* 2005;**46**:206–10 [in Japanese].
9. Kang JX, Leaf A. Protective effects of all-trans-retinoic acid against cardiac arrhythmias induced by isoproterenol, lysophosphatidylcholine or ischemia and reperfusion. *J Cardiovasc Pharmacol* 1995;**26**:943–8.
10. Park JH, Panageas K, Schymura M, Qiao B, Jurcic JG, Rosenblat T, et al. A population-based study in acute promyelocytic leukemia (APL) suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: data from the Surveillance, Epidemiology, and End Results (SEER) program and the New York State Cancer Registry in the United States between 1992–2007. In: *Proceedings of the ASH Annual Meeting, Orlando, FL, 2010, abstract 872*; 2010.